Serum S100B Protein Concentrations in SGA/FGR newborns

Barbara Strzalko1, Agata Karowicz-Bilinska2, Krystyna Wyka3

  • 1Department of Neonatology, Children Clinical Hospital, Medical University of Warsaw, Poland. strzalko.b@gmail.com.

Ginekologia Polska
|June 9, 2021
PubMed

Insights

Elevated S100B protein in cord blood may help detect central nervous system damage in small for gestational age (SGA) newborns. This marker aids in early identification of infants at risk for neurological issues.

Area of Science:

  • Neonatal Medicine
  • Biochemistry
  • Neurology

Background:

  • Fetal growth restriction (FGR) is linked to chronic fetal hypoxia, poor perinatal outcomes, and increased mortality.
  • Currently, reliable methods for detecting central nervous system (CNS) cell damage in FGR infants are lacking.
  • S100B protein, an acidic calcium-binding protein, is a recognized biomarker for CNS damage in infants.

Purpose of the Study:

  • To measure blood S100B protein concentrations in newborns exhibiting small for gestational age (SGA) and appropriate for gestational age (AGA) growth patterns.
  • To determine the utility of S100B as an early indicator for hypoxia-related CNS injury in neonates.

Main Methods:

  • Serum S100B protein levels were analyzed in cord blood from 88 SGA and 80 AGA newborns.
  • Maternal medical records were reviewed for factors like pregnancy-induced hypertension, preeclampsia, smoking, and umbilical artery (UA) Doppler findings.

Main Results:

  • SGA newborns exhibited significantly higher median S100B concentrations compared to AGA controls (p < 0.001).
  • In SGA neonates, cord blood S100B levels were significantly elevated compared to AGA newborns, irrespective of prenatal UA Doppler findings (p < 0.001).

Conclusions:

  • Elevated S100B levels in cord blood of SGA newborns may serve as an early indicator.
  • This biomarker could aid in identifying infants at increased risk for postnatal neurological disturbances.
Abstract

Related Concept Videos